Cause of death in MS: Long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study

BMJ Open

Volumn 2, Issue 6, 2012, Pages

  Goodin, Douglas S ^a   Ebers, George C ^b   Cutter, Gary ^c   Cook, Stuart D ^d   O'Donnell, Timothy ^e   Reder, Anthony T ^f   Kremenchutzky, Marcelo ^g   Oger, Joel ^h   Rametta, Mark ^i,j   Beckmann, Karola ^i,j   Knappertz, Volker ^i,j,k  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^e Pompton Lakes Pulmonary PC   (United States)

^f UNIVERSITY OF CHICAGO   (United States)

^g UNIVERSITY OF WESTERN ONTARIO   (Canada)

^h UNIVERSITY OF BRITISH COLUMBIA   (Canada)

ⁱ BAYER CORPORATION   (United States)

^j BAYER PHARMA AG   (Germany)

^k HEINRICH HEINE UNIVERSITY   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON BETA SERINE; PLACEBO;

ACCIDENTAL DEATH; ADULT; ARTICLE; ASPIRATION PNEUMONIA; BRAIN DYSFUNCTION; BRAIN STEM; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; INFECTION; INJURY; LUNG EMBOLISM; LUNG INFECTION; MAJOR CLINICAL STUDY; MULTIPLE SCLEROSIS; NEOPLASM; NORTH AMERICA; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY FAILURE; SEPSIS; SUICIDE;

EID: 84873850790     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2012-001972     Document Type: Article

References (33)

1. Bronnum-Hansen H, Koch-Henriksen N, Stenager E. Trends in survival and cause of death in Danish patients with multiple sclerosis. Brain 2004;127:844-50. (Pubitemid 38478529)
2. Grytten TN, Lie SA, Aarseth JH, et al. Survival and cause of death in multiple sclerosis: results from a 50-year follow-up in Western Norway. Mult Scler 2008;14:1191-8.
3. Smestad C, Sandvik L, Celius EG. Excess mortality and cause of death in a cohort of Norwegian multiple sclerosis patients. Mult Scler 2009;15:1263-70.
4. Sumelahti ML, Hakama M, Elovaara I, et al. Causes of death among patients with multiple sclerosis. Mult Scler 2010;16:1437-2.
5. Ekestern E, Lebhart G. Mortality from multiple sclerosis in Austria 1970-2001: dynamics, trends, and prospects. Eur J Neurol 2004;11:511-20. (Pubitemid 39062088)
6. Leray E, Morrissey SP, Yaouanq J, et al. Long-term survival of patients with multiple sclerosis in West France. Mult Scler 2007;13:865-74. (Pubitemid 351540857)
7. Ragonese P, Aridon P, Mazzola MA, et al. Multiple sclerosis survival: a population-based study in Sicily. Eur J Neurol 2010;17:391-7.
8. Redelings MD, McCoy L, Sorvillo F. Multiple sclerosis mortality and patterns of comorbidity in the United States from 1990 to 2001. Neuroepidemiology 2006;26:102-7. (Pubitemid 43201305)
9. Liddell FD. Simple exact analysis of the standardised mortality ratio. J Epidemiol Community Health 1984;38:85-8.
10. Andersen PK, Vaeth M. Simple parametric and nonparametric models for excess and relative mortality. Biometrics 1989;45:523-35. (Pubitemid 19165263)
11. Riise T, Gronning M, Aarli JA, et al. Prognostic factors for life expectancy in multiple sclerosis analysed by Cox-models. J Clin Epidemiol 1988;41:1031-6. (Pubitemid 19002072)
12. Wallin MT, Page WF, Kurtzke JF. Epidemiology of multiple sclerosis in US veterans. VIII. Long-term survival after onset of multiple sclerosis. Brain 2000;123(Pt 8):1677-87. (Pubitemid 30481191)
13. Koch-Henriksen N, Bronnum-Hansen H, Stenager E. Underlying cause of death in Danish patients with multiple sclerosis: results from the Danish Multiple Sclerosis Registry. J Neurol Neurosurg Psychiatry 1998;65:56-9. (Pubitemid 28302357)
14. Degenhardt A, Ramagopalan SV, Scalfari A, et al. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol 2009;5:672-82.
15. Cutter G, Reshef S, Golub H, et al. Survival and mortality cause in populations with multiple sclerosis in the United States (MIMS-US) (abstract). Mult Scler 2011;17:S301-2.
16. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology 1993;43:655-61.
17. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. The IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45:1277-85.
18. Goodin DS, Reder AT, Ebers GC, et al. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNB-1b trial. Neurology 2012;78:1315-22.
19. Paty DW, Li DK. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology 1993;43:662-7. (Pubitemid 23121952)
20. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52. (Pubitemid 14237132)
21. Ebers GC, Traboulsee A, Li D, et al. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry 2010;81:907-12.
22. Reder AT, Ebers GC, Traboulsee A, et al. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology 2010;74:1877-5.
23. Bronnum-Hansen H, Stenager E, Hansen T, et al. Survival and mortality rates among Danes with MS. Int MS J 2006;13:66-71. (Pubitemid 43764530)
24. Piantadosi S. Clinical trials: a methodologic perspective. 2nd edn. Hoboken, NY: John Wiley & Sons Inc., 2005.
25. Pocock SJ, Assmann SE, Enos LE, et al. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002;21:2917-30.
26. Goodin DS, Reder AT. Evidence-based medicine: promise and pitfalls. Mult Scler 2012;18:947-8.
27. Goodin DS, Reder AT. Response to the GS Gronseth and E Ashman. Mult Scler 2012;18:1661-2.
28. Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53. (Pubitemid 44454583)
29. Bermel RA, Weinstock-Guttman B, Bourdette D, et al. Intramuscular interferon beta-1a therapy in patients with relapsing-remittingmultiple sclerosis: a 15-year follow-up study. Mult Scler 2010;16:588-96.
30. Ford C, Goodman AD, Johnson K, et al. Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate. Mult Scler 2010;16:342-50.
31. Bisson GP, Gaolathe T, Gross R, et al. Overestimates of survival after HAART: implications for global scale-up efforts. PLoS One 2008;3:e1725.
32. Hirst C, Swingler R, Compston DA, et al. Survival and cause of death in multiple sclerosis: a prospective population-based study. J Neurol Neurosurg Psychiatry 2008;79:1016-21.
33. Phadke JG. Survival pattern and cause of death in patients with multiple sclerosis: results from an epidemiological survey in north east Scotland. J Neurol Neurosurg Psychiatry 1987;50:523-31. (Pubitemid 17067538)